Last reviewed · How we verify
UBX0101
At a glance
| Generic name | UBX0101 |
|---|---|
| Sponsor | Unity Biotechnology, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee (PHASE2)
- Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo
- A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee (PHASE1)
- A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UBX0101 CI brief — competitive landscape report
- UBX0101 updates RSS · CI watch RSS
- Unity Biotechnology, Inc. portfolio CI